MYL12B

Summary

MYL12B (myosin light chain 12B, HGNC:29827) is a protein-coding gene on chromosome 18p11.31, encoding Myosin regulatory light chain 12B (O14950). Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation.

The activity of nonmuscle myosin II (see MYH9; MIM 160775) is regulated by phosphorylation of a regulatory light chain, such as MRLC2. This phosphorylation results in higher MgATPase activity and the assembly of myosin II filaments (Iwasaki et al., 2001 [PubMed 11942626]).

Source: NCBI Gene 103910 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 10 total
• Druggable target: yes
• MANE Select transcript: NM_033546

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29827
Approved symbol	MYL12B
Name	myosin light chain 12B
Location	18p11.31
Locus type	gene with protein product
Status	Approved
Aliases	MRLC2
Ensembl gene	ENSG00000118680
Ensembl biotype	protein_coding
OMIM	609211
Entrez	103910

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000237500, ENST00000400175, ENST00000581193, ENST00000584539, ENST00000648965, ENST00000874764, ENST00000874765, ENST00000874766, ENST00000918456, ENST00000918457, ENST00000965090

RefSeq mRNA: 3 — MANE Select: NM_033546 NM_001144944, NM_001144945, NM_033546

CCDS: CCDS11831

Canonical transcript exons

ENST00000237500 — 4 exons

Exon	Start	End
ENSE00000800184	3272884	3273082
ENSE00001207798	3262133	3262237
ENSE00001749122	3277253	3277414
ENSE00003900833	3277765	3278461

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 99.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 329.0447 / max 3722.8457, expressed in 1827 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
169156	164.4200	1825
169155	163.8591	1825
169158	0.2073	108
169154	0.1989	79
169159	0.1455	80
169160	0.1256	45
169157	0.0883	37

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gingival epithelium	UBERON:0001949	99.69	gold quality
pancreatic ductal cell	CL:0002079	99.66	gold quality
colonic mucosa	UBERON:0000317	99.65	gold quality
gingiva	UBERON:0001828	99.64	gold quality
mucosa of sigmoid colon	UBERON:0004993	99.61	gold quality
metanephros cortex	UBERON:0010533	99.61	gold quality
esophagus squamous epithelium	UBERON:0006920	99.59	gold quality
right lung	UBERON:0002167	99.57	gold quality
jejunal mucosa	UBERON:0000399	99.55	gold quality
renal medulla	UBERON:0000362	99.53	gold quality
mucosa of transverse colon	UBERON:0004991	99.52	gold quality
squamous epithelium	UBERON:0006914	99.51	gold quality
epithelium of esophagus	UBERON:0001976	99.49	gold quality
islet of Langerhans	UBERON:0000006	99.48	gold quality
mammalian vulva	UBERON:0000997	99.48	gold quality
right adrenal gland	UBERON:0001233	99.48	gold quality
amniotic fluid	UBERON:0000173	99.47	gold quality
left adrenal gland	UBERON:0001234	99.47	gold quality
mammary duct	UBERON:0001765	99.47	gold quality
rectum	UBERON:0001052	99.46	gold quality
left lobe of thyroid gland	UBERON:0001120	99.46	gold quality
adrenal cortex	UBERON:0001235	99.46	gold quality
right adrenal gland cortex	UBERON:0035827	99.46	gold quality
palpebral conjunctiva	UBERON:0001812	99.45	gold quality
placenta	UBERON:0001987	99.45	gold quality
nasal cavity epithelium	UBERON:0005384	99.45	gold quality
upper lobe of left lung	UBERON:0008952	99.45	gold quality
left adrenal gland cortex	UBERON:0035825	99.45	gold quality
right lobe of thyroid gland	UBERON:0001119	99.43	gold quality
upper lobe of lung	UBERON:0008948	99.43	gold quality

Single-cell (SCXA)

Detected in 17 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	2020.50
E-CURD-122	yes	45.12
E-HCAD-11	yes	39.96
E-MTAB-6701	yes	36.95
E-GEOD-81547	yes	24.50
E-HCAD-1	yes	16.90
E-HCAD-9	yes	15.16
E-MTAB-8410	yes	15.09
E-MTAB-10042	yes	8.40
E-ENAD-27	yes	6.37
E-GEOD-130148	yes	6.03
E-MTAB-8495	no	3070.66
E-GEOD-81383	no	1781.44
E-CURD-46	no	10.98
E-MTAB-9388	no	6.88

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

29 targeting MYL12B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-6128	99.33	67.83	1581
HSA-MIR-499A-3P	99.18	69.20	1392
HSA-MIR-499B-3P	99.18	69.27	1391
HSA-MIR-622	98.99	66.48	1050
HSA-MIR-548AO-5P	98.55	69.57	1362
HSA-MIR-548AX	98.55	69.58	1362
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-6730-5P	98.03	68.12	1299
HSA-MIR-3920	97.75	69.02	1168
HSA-MIR-495-5P	97.62	68.28	682
HSA-MIR-937-5P	97.43	68.39	667
HSA-MIR-6729-3P	96.91	66.79	703
HSA-MIR-5702	96.68	68.21	958
HSA-MIR-8081	96.42	67.75	738
HSA-MIR-5586-5P	96.29	68.02	685

Literature-anchored findings (GeneRIF, showing 5)

• These results suggest that EGCG inhibits the cell growth by reducing the MRLC phosphorylation and this effect is mediated by the 67LR. (PMID:15946647)
• Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. (PMID:19165527)
• The study data show that manipulation of the activation sites (Thr18/Ser19) significantly alters myosin II function in a number of these assays while manipulation of the putative inhibitory sites (Ser1/Ser2/Thr9) does not. (PMID:22136066)
• These results suggest that 2P-MRLC has a role different from that of 1P-MRLC at the midzone, and is not a subunit of myosin II. (PMID:22166199)
• phosphorylated MRLC temporally controls its own accumulation, but not that of actin, in cultured mammalian cells. (PMID:22374324)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	myl12.2	ENSDARG00000025326
mus_musculus	Myl12b	ENSMUSG00000034868
rattus_norvegicus	Myl12b	ENSRNOG00000091388
caenorhabditis_elegans		WBGENE00003369
caenorhabditis_elegans		WBGENE00003370

Paralogs (7): MYL9 (ENSG00000101335), MYL12A (ENSG00000101608), MYL10 (ENSG00000106436), MYL7 (ENSG00000106631), MYL2 (ENSG00000111245), MYL11 (ENSG00000180209), MYL5 (ENSG00000215375)

Protein

Protein identifiers

Myosin regulatory light chain 12B — O14950 (reviewed: O14950)

Alternative names: MLC-2A, Myosin regulatory light chain 2-B, smooth muscle isoform, Myosin regulatory light chain 20 kDa, Myosin regulatory light chain MRLC2, SHUJUN-1

All UniProt accessions (1): O14950

UniProt curated annotations — full annotation on UniProt →

Function. Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation. Phosphorylation triggers actin polymerization in vascular smooth muscle. Implicated in cytokinesis, receptor capping, and cell locomotion.

Subunit / interactions. Myosin is a hexamer of 2 heavy chains and 4 light chains: interacts with myosin heavy chain MYO19.

Tissue specificity. Ubiquitously expressed in various hematopoietic cells.

Post-translational modifications. Phosphorylation increases the actin-activated myosin ATPase activity and thereby regulates the contractile activity. It is required to generate the driving force in the migration of the cells but not necessary for localization of myosin-2 at the leading edge. Phosphorylation is reduced following epigallocatechin-3-O-gallate treatment.

Miscellaneous. This chain binds calcium.

RefSeq proteins (3): NP_001138416, NP_001138417, NP_291024* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR015070	EF_hand_DJBP	Domain
IPR018247	EF_Hand_1_Ca_BS	Binding_site
IPR050403	Myosin_RLC	Family

Pfam: PF08976, PF13499

UniProt features (19 total): sequence conflict 4, binding site 4, domain 3, modified residue 2, mutagenesis site 2, chain 1, sequence variant 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O14950-F1	83.78	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 42; 44; 46; 53

Post-translational modifications (2): 19, 20

Mutagenesis-validated functional residues (2):

Position	Phenotype
19–20	shows a decrease in the number of actin filament bundles.
19–20	shows a larger number of actin filament bundles.

Function

Pathways and Gene Ontology

Reactome pathways

18 pathways

ID	Pathway
R-HSA-3928663	EPHA-mediated growth cone collapse
R-HSA-416572	Sema4D induced cell migration and growth-cone collapse
R-HSA-445355	Smooth Muscle Contraction
R-HSA-5625740	RHO GTPases activate PKNs
R-HSA-5625900	RHO GTPases activate CIT
R-HSA-5627117	RHO GTPases Activate ROCKs
R-HSA-5627123	RHO GTPases activate PAKs
R-HSA-1266738	Developmental Biology
R-HSA-162582	Signal Transduction
R-HSA-194315	Signaling by Rho GTPases
R-HSA-195258	RHO GTPase Effectors
R-HSA-2682334	EPH-Ephrin signaling
R-HSA-373755	Semaphorin interactions
R-HSA-397014	Muscle contraction
R-HSA-400685	Sema4D in semaphorin signaling
R-HSA-422475	Axon guidance
R-HSA-9675108	Nervous system development
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 200 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, MODULE_151, MORI_IMMATURE_B_LYMPHOCYTE_UP, KEGG_TIGHT_JUNCTION, RIZKI_TUMOR_INVASIVENESS_3D_DN, CAIRO_HEPATOBLASTOMA_CLASSES_DN, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP, REACTOME_SMOOTH_MUSCLE_CONTRACTION, LAIHO_COLORECTAL_CANCER_SERRATED_UP, MODULE_114, GOBP_REGULATION_OF_CELL_SHAPE, GOCC_I_BAND, GOCC_APICAL_PART_OF_CELL, GOCC_ACTIN_FILAMENT_BUNDLE

GO Biological Process (1): regulation of cell shape (GO:0008360)

GO Molecular Function (4): calcium ion binding (GO:0005509), myosin heavy chain binding (GO:0032036), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (12): stress fiber (GO:0001725), cytoplasm (GO:0005737), cytosol (GO:0005829), brush border (GO:0005903), cell cortex (GO:0005938), myosin II complex (GO:0016460), myofibril (GO:0030016), Z disc (GO:0030018), extracellular exosome (GO:0070062), myosin complex (GO:0016459), protein-containing complex (GO:0032991), apical part of cell (GO:0045177)

Reactome top-level categories

Rollup of top-11 pathways:

Category	Pathways
RHO GTPase Effectors	4
Axon guidance	2
EPH-Ephrin signaling	1
Sema4D in semaphorin signaling	1
Muscle contraction	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Semaphorin interactions	1
Nervous system development	1
Developmental Biology	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
cytoplasm	2
regulation of cell morphogenesis	1
regulation of biological quality	1
metal ion binding	1
myosin binding	1
binding	1
cation binding	1
actomyosin	1
contractile actin filament bundle	1
intracellular anatomical structure	1
microvillus	1
apical part of cell	1
cluster of actin-based cell projections	1
cell periphery	1
myosin complex	1
contractile muscle fiber	1
I band	1
extracellular vesicle	1
actin cytoskeleton	1
protein-containing complex	1
cellular_component	1

Protein interactions and networks

STRING

2724 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYL12B	CNPY2	Q9Y2B0	827
MYL12B	MYH9	P35579	809
MYL12B	MYOD1	P15172	774
MYL12B	PPP1R12A	O14974	756
MYL12B	MYLIP	Q8WY64	684
MYL12B	RHOA	P06749	671
MYL12B	MYLK3	Q32MK0	657
MYL12B	PPP1R14A	Q96A00	639
MYL12B	MYL6	P16475	595
MYL12B	ROCK1	Q13464	568
MYL12B	MYH7	P12883	567
MYL12B	PPP1R12C	Q9BZL4	536
MYL12B	ROCK2	O75116	530
MYL12B	XPR1	Q9UBH6	497
MYL12B	MYBPC2	Q14324	495

IntAct

98 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
MYH9	MYL12B	psi-mi:“MI:0914”(association)	0.640
MYL12B	NSMF	psi-mi:“MI:0915”(physical association)	0.560
MYL12B	MYH11	psi-mi:“MI:0915”(physical association)	0.560
ACTB	MYL12B	psi-mi:“MI:0915”(physical association)	0.540
MYL12B	ACTB	psi-mi:“MI:0914”(association)	0.540
ACTB	MYL12B	psi-mi:“MI:0403”(colocalization)	0.540
MYO19	MYL12B	psi-mi:“MI:0914”(association)	0.530
VCAM1	PSMD11	psi-mi:“MI:0914”(association)	0.530
UBE3B	MYL12B	psi-mi:“MI:0915”(physical association)	0.500
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
	MYL12B	psi-mi:“MI:0914”(association)	0.460
MYL12B	DAPK3	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
MYL12B	ACTA2	psi-mi:“MI:0403”(colocalization)	0.430
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400
MYL12B	HSPB1	psi-mi:“MI:0915”(physical association)	0.370
FOXD3	MYL12B	psi-mi:“MI:0914”(association)	0.350
FOXP1	MYL12B	psi-mi:“MI:0914”(association)	0.350
Prkaa1	MYL12B	psi-mi:“MI:0914”(association)	0.350
Prkab1	MYL12B	psi-mi:“MI:0914”(association)	0.350
PLEKHA7	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
OCRL	MYO1C	psi-mi:“MI:0914”(association)	0.350

BioGRID (173): MYL12B (Affinity Capture-MS), MYL12B (Two-hybrid), MYL12B (Affinity Capture-MS), MYL12B (Affinity Capture-MS), MYL12B (Affinity Capture-MS), MYL12B (Affinity Capture-MS), MYL12B (Affinity Capture-MS), PA2G4 (Affinity Capture-MS), TRAP1 (Affinity Capture-MS), SND1 (Affinity Capture-MS), CPSF6 (Affinity Capture-MS), UBE2N (Affinity Capture-MS), MYL12B (Affinity Capture-MS), MYL12B (Affinity Capture-MS), MYL12B (Affinity Capture-MS)

ESM2 similar proteins: A0A125YHX7, A0A125YZN2, A4IF97, J9W034, O14950, O23184, O74435, O82659, P02612, P08733, P13832, P15845, P18666, P19105, P24032, P24844, P29269, P40423, P41208, P41209, P41210, P41691, P48593, P53441, Q09510, Q0IQB6, Q0IUU4, Q12798, Q24956, Q27177, Q27178, Q27179, Q2TBN3, Q32LE3, Q338P8, Q39584, Q3SEK0, Q3SEK2, Q3THE2, Q40642

Diamond homologs: A2WN93, A2WNH1, A2Y609, A3E3H0, A3E4D8, A3E4F9, A4IF97, A4UHC0, A8CEP3, A8I1Q0, B7SNI3, F1SSF9, O14950, O93409, O94739, P02597, P02598, P02608, P02609, P02610, P02611, P02612, P02613, P04112, P04113, P04353, P04464, P04466, P05419, P05944, P05963, P07461, P08051, P08052, P08733, P0DH95, P0DH96, P10916, P11120, P13543

SIGNOR signaling

10 interactions.

A	Effect	B	Mechanism
ILK	“up-regulates activity”	MYL12B	phosphorylation
MAP3K12	up-regulates	MYL12B	phosphorylation
DAPK3	up-regulates	MYL12B	phosphorylation
ROCK2	“up-regulates activity”	MYL12B	phosphorylation
PAK1	“up-regulates activity”	MYL12B	phosphorylation
ROCK1	up-regulates	MYL12B	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 100 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Oncogenic MAPK signaling	5	20.0×	1e-03
Signaling by BRAF and RAF1 fusions	6	16.5×	9e-04
Activation of STAT3 by cadherin engagement	5	13.2×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

10 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	5
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

564 predictions. Top by Δscore:

Variant	Effect	Δscore
18:3262139:G:GT	donor_gain	1.0000
18:3272877:A:AG	acceptor_gain	1.0000
18:3272878:A:G	acceptor_gain	1.0000
18:3272879:TCCAG:T	acceptor_loss	1.0000
18:3272882:A:AC	acceptor_loss	1.0000
18:3272882:A:AG	acceptor_gain	1.0000
18:3272883:G:GG	acceptor_gain	1.0000
18:3272883:GA:G	acceptor_gain	1.0000
18:3272883:GAA:G	acceptor_gain	1.0000
18:3272883:GAAT:G	acceptor_gain	1.0000
18:3272883:GAATT:G	acceptor_gain	1.0000
18:3273052:G:T	donor_gain	1.0000
18:3273052:GAAGA:G	donor_gain	1.0000
18:3273053:A:T	donor_gain	1.0000
18:3273065:A:G	donor_gain	1.0000
18:3277244:T:G	acceptor_gain	1.0000
18:3277249:ACAG:A	acceptor_gain	1.0000
18:3277250:C:G	acceptor_gain	1.0000
18:3277250:CA:C	acceptor_loss	1.0000
18:3277251:A:AG	acceptor_gain	1.0000
18:3277251:A:AT	acceptor_loss	1.0000
18:3277251:AG:A	acceptor_gain	1.0000
18:3277251:AGG:A	acceptor_gain	1.0000
18:3277252:G:GC	acceptor_gain	1.0000
18:3277252:GG:G	acceptor_gain	1.0000
18:3277252:GGG:G	acceptor_gain	1.0000
18:3277252:GGGA:G	acceptor_gain	1.0000
18:3277252:GGGAA:G	acceptor_gain	1.0000
18:3277410:AACAG:A	donor_gain	1.0000
18:3277411:ACAG:A	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000145143 (18:3275045 C>T), RS1000271933 (18:3263728 TCTTC>T), RS1000451010 (18:3269261 G>T), RS1000699477 (18:3273798 G>A,T), RS1000737064 (18:3269472 A>G), RS1000897054 (18:3274828 T>C), RS1001017278 (18:3267263 T>G), RS1001191559 (18:3270527 C>G), RS1001219292 (18:3262263 G>C), RS1001319257 (18:3270800 A>T), RS1001343964 (18:3268155 A>G), RS1001471215 (18:3267471 A>G), RS1001795086 (18:3268466 A>T), RS1002133871 (18:3264471 A>G), RS1002233309 (18:3260787 C>T)

Disease associations

OMIM: gene MIM:609211 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002408_15	Response to methotrexate in juvenile idiopathic arthritis	5.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295652 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, increases expression	4
Valproic Acid	increases expression, decreases methylation	3
sodium arsenite	decreases expression, increases expression	2
Estradiol	affects cotreatment, decreases expression	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Dronabinol	decreases expression, increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
aristolochic acid I	decreases expression	1
moringin	affects cotreatment, increases expression	1
dicrotophos	decreases expression	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
decabromobiphenyl ether	decreases expression	1
tetrabromobisphenol A	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Acetaminophen	decreases expression	1
Cannabidiol	affects cotreatment, increases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Bucladesine	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Diuron	decreases expression	1
Doxorubicin	increases expression	1
Methotrexate	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118949	Binding	Binding affinity to MYL12B in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.